Private TRT clinic vs self-prescribing: what the evidence says

What's this video probably claiming?

Based on the caption and hashtag context, @carlglifts is likely walking viewers through a practical comparison of two routes men use to access testosterone replacement therapy: going through a private clinic (think structured consultations, blood panels, prescriptions) versus self-prescribing, which in the UK typically means sourcing testosterone from grey-market suppliers without medical oversight. The video probably frames both options as legitimate lifestyle choices, possibly suggesting self-prescribing is cheaper and more flexible, while acknowledging the clinic route offers some degree of safety or legitimacy. Given the "hormone optimization" framing that dominates TRT content, there's a reasonable chance the video treats hypogonadism as a spectrum where men can self-diagnose based on symptoms like fatigue or low libido, rather than a clinical diagnosis requiring confirmed low serum testosterone on at least two morning blood draws.

What does the science actually show?

The clinical picture on TRT is more complicated than most TikTok content admits. Diagnosed hypogonadism, defined as total testosterone consistently below 300 ng/dL alongside symptoms, does respond to testosterone therapy. The 2018 Testosterone Trials, a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine, found meaningful improvements in sexual function and bone density in men over 65 with confirmed low testosterone, but modest and inconsistent effects on energy and mood. Crucially, cardiovascular risk is not settled. Baillargeon et al. (2014, JAMA Internal Medicine) found an association between TRT initiation and increased myocardial infarction risk in older men. The FDA added a warning in 2015 requiring labels to note potential cardiovascular risk. Self-dosing without regular haematocrit monitoring is particularly concerning, as testosterone consistently raises red blood cell mass, increasing clotting risk at haematocrit levels above 54 percent.

Where does the social media noise diverge from clinical reality?

The biggest gap between TRT TikTok and actual clinical practice is who qualifies. Social media content routinely presents testosterone as a fix for anyone feeling tired, mentally foggy, or under-muscled. But Handelsman (2020, Endocrine Reviews) estimated that the majority of men seeking TRT in private settings have testosterone levels within normal range and are being treated primarily for subjective wellbeing, not documented hypogonadism. Private clinics vary enormously in their diagnostic rigour. Some follow British Society for Sexual Medicine guidelines. Others diagnose from a single blood draw, sometimes taken at sub-optimal times, and skip free testosterone or SHBG measurements entirely. As for self-prescribing, the grey-market reality includes inconsistent product purity, zero monitoring for polycythaemia or prostate-specific antigen changes, and no pathway to address side effects like testicular atrophy or infertility, which require concurrent HCG or post-cycle planning that demands actual medical input.

What should you actually know?

If you are genuinely investigating whether TRT is right for you, the private clinic versus self-prescribing framing is almost the wrong question. The right starting point is whether you actually have hypogonadism confirmed by two early-morning blood tests showing low total and free testosterone, alongside clinical symptoms. A good clinic orders a full panel including LH, FSH, prolactin, and SHBG, rules out secondary causes like sleep apnoea or obesity, and monitors you at three and six months. If a clinic is not doing this, it is not a clinic doing TRT properly. Self-prescribing skips all of that, and the risk is not just legal. Without baseline PSA, haematocrit monitoring, and cardiovascular risk assessment, you are running an unsupervised experiment on your endocrine system. For men under 40, the fertility implications alone warrant specialist input, as exogenous testosterone suppresses sperm production, sometimes irreversibly without intervention.